Praxis Precision Medicines (PRAX) PEG Ratio: History & Chart

Praxis Precision Medicines, Inc.(PRAX)

Biotechnology · Boston, MA

$280.14-3.42 (-1.21%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Boston, MA

168 employees

www.praxismedicines.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marcio Silva De'Souza

View full financials

NAME	MARKET CAP	PEG RATIO	TTM	3Y	5Y
Praxis Precision Medicines, Inc. (PRAX)	$7.81B	N/A	N/A	N/A	N/A
Caris Life Sciences, Inc. (CAI)vs ›	$7.76B	N/A	N/A	N/A	N/A
Cytokinetics, Incorporated (CYTK)vs ›	$7.63B	N/A	N/A	N/A	N/A
TG Therapeutics, Inc. (TGTX)vs ›	$7.99B	N/A	N/A	N/A	N/A
HealthEquity, Inc. (HQY)vs ›	$7.61B	0.40	1.77	3.07	3.07
Hinge Health, Inc. (HNGE)vs ›	$7.61B	N/A	N/A	N/A	N/A
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.31B	N/A	N/A	N/A	N/A
Oscar Health, Inc. (OSCR)vs ›	$8.38B	N/A	N/A	N/A	N/A
Alkermes plc (ALKS)vs ›	$6.99B	N/A	N/A	N/A	N/A
Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›	$8.67B	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PEG RATIO

TTM

Praxis Precision Medicines, Inc. (PRAX)

$7.81B

N/A

Caris Life Sciences, Inc. (CAI)vs ›

$7.76B

N/A

Cytokinetics, Incorporated (CYTK)vs ›

$7.63B

N/A

TG Therapeutics, Inc. (TGTX)vs ›

$7.99B

N/A

HealthEquity, Inc. (HQY)vs ›

$7.61B

0.40

1.77

3.07

Hinge Health, Inc. (HNGE)vs ›

$7.61B

N/A

Ionis Pharmaceuticals, Inc. (IONS)vs ›

$7.31B

N/A

Oscar Health, Inc. (OSCR)vs ›

$8.38B

N/A

Alkermes plc (ALKS)vs ›

$6.99B

N/A

Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›

$8.67B

N/A

PEG Ratio Formula & Definition

PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)

The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.

PEG Ratio: N/A

PRAX PEG Ratio Metrics

PRAX Competitors' PEG Ratio

Growth-Adjusted Valuation

PEG Ratio Formula & Definition

Related Metrics